Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 70

1.

The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study.

Byun JH, Ahn JB, Kim SY, Kang JH, Zang DY, Kang SY, Kang MJ, Shim BY, Baek SK, Kim BS, Lee KH, Lee SI, Cho SH, Sohn BS, Kim S, Hwang IG, Nam EM, Seo BG, Oh SC, Lee MA, Lee SC, Hong JH, Park YS.

Korean J Intern Med. 2017 Nov 28. doi: 10.3904/kjim.2016.348. [Epub ahead of print]

2.

Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.

Kwak JY, Kim SH, Oh SJ, Zang DY, Kim H, Kim JA, Do YR, Kim HJ, Park JS, Choi CW, Lee WS, Mun YC, Kong JH, Chung JS, Shin HJ, Kim DY, Park J, Jung CW, Bunworasate U, Comia NS, Jootar S, Reksodiputro AH, Caguioa PB, Lee SE, Kim DW.

Clin Cancer Res. 2017 Dec 1;23(23):7180-7188. doi: 10.1158/1078-0432.CCR-17-0957. Epub 2017 Sep 22.

PMID:
28939746
3.

Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia.

Lee JH, Kim H, Joo YD, Lee WS, Bae SH, Zang DY, Kwon J, Kim MK, Lee J, Lee GW, Lee JH, Choi Y, Kim DY, Hur EH, Lim SN, Lee SM, Ryoo HM, Kim HJ, Hyun MS, Lee KH; Cooperative Study Group A for Hematology.

J Clin Oncol. 2017 Aug 20;35(24):2754-2763. doi: 10.1200/JCO.2017.72.8618. Epub 2017 Jun 20.

PMID:
28632487
4.

Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.

Kim JW, Lee KW, Kim KP, Lee JH, Hong YS, Kim JE, Kim SY, Park SR, Nam BH, Cho SH, Chung IJ, Park YS, Oh HS, Lee MA, Kang HJ, Park YI, Song EK, Han HS, Lee KT, Shin DB, Kang JH, Zang DY, Kim JH, Kim TW.

Oncologist. 2017 Mar;22(3):293-303. doi: 10.1634/theoncologist.2016-0166. Epub 2017 Feb 16.

PMID:
28209749
5.

Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review.

Kim BJ, Kim JH, Kim HS, Zang DY.

Oncotarget. 2017 Feb 21;8(8):13979-13985. doi: 10.18632/oncotarget.14704. Review.

6.

A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer.

Han B, Jung JY, Kim HS, Cho JW, Kim KC, Lim H, Kang HS, Ha HI, Kim MJ, Kim JH, Choi DR, Jang G, Kim JH, Song H, Zang DY.

Cancer Chemother Pharmacol. 2016 Nov;78(5):949-958. Epub 2016 Sep 15.

PMID:
27628195
7.

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.

Lee SE, Choi SY, Song HY, Kim SH, Choi MY, Park JS, Kim HJ, Kim SH, Zang DY, Oh S, Kim H, Do YR, Kwak JY, Kim JA, Kim DY, Mun YC, Lee WS, Chang MH, Park J, Kwon JH, Kim DW.

Haematologica. 2016 Jun;101(6):717-23. doi: 10.3324/haematol.2015.139899. Epub 2016 Feb 17.

8.

Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1.

Jung JY, Ryu MH, Ryoo BY, Han B, Cho JW, Lim MS, Lim H, Kang HS, Kim MJ, Ha HI, Song H, Kim JH, Kim HS, Kang YK, Zang DY.

Gastroenterol Res Pract. 2016;2016:6857625. doi: 10.1155/2016/6857625. Epub 2015 Dec 29.

9.

Clinical Outcome and Predictive Factors in the Response to Splenectomy in Elderly Patients with Primary Immune Thrombocytopenia: A Multicenter Retrospective Study.

Park YH, Yi HG, Kim CS, Hong J, Park J, Lee JH, Kim HY, Kim HJ, Zang DY, Kim SH, Park SK, Hong DS, Lee GJ, Jin JY; Gyeonggi/Incheon Branch, The Korean Society of Hematology.

Acta Haematol. 2016;135(3):162-71. doi: 10.1159/000442703. Epub 2016 Jan 16.

PMID:
26771656
10.

Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses.

Noh H, Park MS, Kim SH, Oh SJ, Zang DY, Park HL, Cho DJ, Kim DW, Lee JI.

Leuk Lymphoma. 2016 Aug;57(8):1856-64. doi: 10.3109/10428194.2015.1113278. Epub 2015 Dec 15.

PMID:
26666371
11.

A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer.

Kim JH, Zang DY, Chung IJ, Cho SH, Park KU, Oh HS, Lee KH, Lee BH, Kim MJ, Park CK, Han B, Kim HS, Choi DR, Song HH, Jung JY.

J Cancer. 2015 Aug 29;6(10):1041-8. doi: 10.7150/jca.12819. eCollection 2015.

12.

Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.

Bang YJ, Im SA, Lee KW, Cho JY, Song EK, Lee KH, Kim YH, Park JO, Chun HG, Zang DY, Fielding A, Rowbottom J, Hodgson D, O'Connor MJ, Yin X, Kim WH.

J Clin Oncol. 2015 Nov 20;33(33):3858-65. doi: 10.1200/JCO.2014.60.0320. Epub 2015 Aug 17.

PMID:
26282658
13.

Phase I/II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer.

Lee KW, Lee KH, Zang DY, Park YI, Shin DB, Kim JW, Im SA, Koh SA, Yu KS, Cho JY, Jung JA, Bang YJ.

Oncologist. 2015 Aug;20(8):896-7. doi: 10.1634/theoncologist.2015-0202. Epub 2015 Jun 25.

14.

Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer.

Kim HS, Ryu MH, Zang DY, Ryoo BY, Yang DH, Cho JW, Lim MS, Kim MJ, Han B, Choi DR, Kim JH, Jung JY, Song H, Park CK, Kang YK.

Gastric Cancer. 2016 Apr;19(2):579-85. doi: 10.1007/s10120-015-0503-2. Epub 2015 May 22.

PMID:
25997815
15.

Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients.

Park JS, Lee SE, Jeong SH, Jang EJ, Choi MY, Kim HJ, Kim YK, Kim SH, Zang DY, Oh S, Koo DH, Kim H, Do YR, Kwak JY, Kim JA, Kim DY, Mun YC, Lee WS, Chang MH, Park J, Kwon JH, Kim DW.

Leuk Lymphoma. 2015 Jun 12:1-7. [Epub ahead of print]

PMID:
25947037
16.

A satisfaction survey on cancer pain management using a self-reporting pain assessment tool.

Lim SN, Han HS, Lee KH, Lee SC, Kim J, Yun J, Park S, Park M, Choe Y, Ryoo HM, Lee K, Cho D, Zang DY, Choi J.

J Palliat Med. 2015 Mar;18(3):225-31. doi: 10.1089/jpm.2014.0021. Epub 2015 Feb 4.

PMID:
25650504
17.

The Clinical Utility of FDG PET-CT in Evaluation of Bone Marrow Involvement by Lymphoma.

Kim HY, Kim JS, Choi DR, Kim HS, Kwon JH, Jang GD, Kim JH, Jung JY, Song HH, Lee YK, Min SK, Hwang HS, Kim HJ, Zang DY, Kim HJ.

Cancer Res Treat. 2015 Jul;47(3):458-64. doi: 10.4143/crt.2014.091. Epub 2014 Nov 24.

18.

A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer.

Choi DR, Yoon SN, Kim HS, Kim JH, Kim KY, Kim BC, Choi YK, Kim JB, Han B, Song HH, Zang DY.

Cancer Chemother Pharmacol. 2015 Mar;75(3):639-43. doi: 10.1007/s00280-015-2688-9. Epub 2015 Jan 29.

PMID:
25630415
19.

Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.

Kim HS, Kim HY, Zang DY, Oh HS, Jeon JY, Cho JW, Park CK, Kim JH, Kim MJ, Ha HI, Kim JH, Han B, Song H, Kwon JH, Choi DR, Jung JY.

Cancer Chemother Pharmacol. 2015 Apr;75(4):711-8. doi: 10.1007/s00280-015-2687-x. Epub 2015 Jan 29.

PMID:
25630414
20.

Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia.

Kim H, Lee WS, Lee KH, Bae SH, Kim MK, Joo YD, Zang DY, Jo JC, Lee SM, Lee JH, Lee JH, Kim DY, Ryoo HM, Hyun MS, Kim HJ; CoOperative Study Group A for Hematology (COSAH).

Ann Hematol. 2015 May;94(5):739-46. doi: 10.1007/s00277-014-2268-9. Epub 2014 Dec 13.

PMID:
25501820

Supplemental Content

Loading ...
Support Center